Get the Stockscreener App
3.70
1.09%
0.04
After Hours:
3.57
-0.13
-3.51%
Cosciens Biopharma Inc stock is traded at $3.70, with a volume of 9,716.
It is up +1.09% in the last 24 hours and up +44.51% over the past month.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
See More
Previous Close:
$3.66
Open:
$3.44
24h Volume:
9,716
Relative Volume:
0.42
Market Cap:
$9.86M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+18.02%
1M Performance:
+44.51%
6M Performance:
-3.12%
1Y Performance:
+0.00%
1-Day Range:
$3.3145
$3.80
1-Week Range:
$3.12
$3.80
52-Week Range:
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
Compare CSCI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
3.70 | 9.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cosciens Biopharma Inc Stock (CSCI) Latest News
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
COSCIENS Biopharma names Anna Biehn as new CEO By Investing.com - Investing.com South Africa
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023) - simplywall.st
COSCIENS Biopharma names Anna Biehn as new CEO - Investing.com Australia
Cosciens Biopharma appoints Biehn as CEO - TipRanks
COSCIENS Biopharma Appoints Anna Biehn as New CEO to Drive Growth in Natural-Based Products - TipRanks
Cosciens Biopharma Appoints Anna Biehn as Chief Executive Officer - marketscreener.com
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - The Manila Times
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023) - Yahoo Finance
COSCIENS Biopharma Reports Revenue Growth and Strategic Repositioning - MSN
Cosciens Biopharma Charts New Path Following Ceapro Merger - Finimize
COSCIENS Biopharma reports Q4 and full year 2024 results - Investing.com Australia
COSCIENS Biopharma: Q4 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q4 and full year 2024 results By Investing.com - Investing.com South Africa
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 202 - GuruFocus
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Natural Products Drive COSCIENS Growth: Revenue Jumps 35% as Pipeline Advances - Stock Titan
COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays - TipRanks
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Lelezard
COSCIENS Biopharma Faces Trading Halt: What Investors Need to Know - AInvest
Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports - Stock Titan
Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey
COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener
Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - MarketScreener
COSCIENS Biopharma flags potential reporting delay - Investing.com
COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks
Cosciens Biopharma Inc Stock (CSCI) Financials Data
There is no financial data for Cosciens Biopharma Inc (CSCI). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):